source
- FDA approves Tregzi, first T‑reg cell therapy to lower chronic GVHD risk in blood‑cancer transplantsThe FDA announced approval of Tregzi, a regulatory T‑cell based immunotherapy designed to improve chronic graft‑versus‑host disease‑free survival for adults with blood cancers undergoing allogeneic…
- FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug ManufacturingFDA announces the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American global competitiveness, strengthen domestic drug manufac…fda press · 1mo ago↗ source